ProMIS Neuroscience is a drug discovery and development company that uses its EpiSelect™ computational platform to identify disease-specific epitopes on toxic, misfolded proteins and develop selective monoclonal antibodies and vaccine candidates targeting these conformational targets. The company's lead programs focus on neurodegenerative diseases including Alzheimer's disease, amyotrophic lateral sclerosis, Parkinson's disease, and related conditions affecting millions of patients globally for which current treatments have limited efficacy. ProMIS generates revenue through research funding, license fees, milestone payments, and royalties from out-licensing its drug candidates to pharmaceutical partners, while building a patent portfolio covering computational algorithms, disease-specific epitopes, and therapeutic antibodies with protection extending multiple decades.